Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib.
Authors : La Rosée P, Martiat P, Leitner A, Klag T, Müller MC, Erben P, Schenk T, Saussele S, Hochhaus A
Year : 2013
Journal : Ann Hematol
Volume : 92(10)
Pages : 1345-50